Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Shouyan Deng"'
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 11 (2023)
Introduction: Cancer biomarkers are substances or processes highly associated with the presence and progression of cancer, which are applicable for cancer screening, progression surveillance, and prognosis prediction in clinical practice. In our prev
Externí odkaz:
https://doaj.org/article/228a88cd38664a458c4e73e0bd7c1a01
Publikováno v:
Cancer Biology & Medicine, Vol 17, Iss 3, Pp 583-598 (2020)
Cancer immunotherapy harness the body’s immune system to eliminate cancer, by using a broad panel of soluble and membrane proteins as therapeutic targets. Immunosuppression signaling mediated by ligand-receptor interaction may be blocked by monoclo
Externí odkaz:
https://doaj.org/article/904030ac70a8457f852db46e163c5780
Autor:
Ke Xu, Jing-Yuan Fang, Dawei Chen, Yungang Wang, Chushu Li, Hao Chi, Shouyan Deng, Huanbin Wang, Han Yao, Xun Guo, Fang He
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background The abnormal upregulation of programmed death-ligand 1 (PD-L1) in cancer cells inhibits T cell-mediated cytotoxicity, but the molecular mechanisms that drive and maintain PD-L1 expression are still incompletely understood.Methods Combined
Externí odkaz:
https://doaj.org/article/fb4bdb331d26404195df7fc852c22622
Publikováno v:
Frontiers in Cell & Developmental Biology; 2023, p1-10, 10p
The LILRB4 myeloid receptor has been implicated in an immunosuppressive microenvironment, with specific antibodies under preclinical or clinical development for tumor immunotherapy. However, it remains largely unknown which natural ligand may trigger
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4551b0cf4ae1d24fcb93ace92a749225
https://doi.org/10.1101/2022.07.27.501694
https://doi.org/10.1101/2022.07.27.501694
Publikováno v:
Cancer Biology & Medicine, Vol 17, Iss 3, Pp 583-598 (2020)
Cancer Biology & Medicine
Cancer Biology & Medicine
Cancer immunotherapy harness the body's immune system to eliminate cancer, by using a broad panel of soluble and membrane proteins as therapeutic targets. Immunosuppression signaling mediated by ligand-receptor interaction may be blocked by monoclona
The immune system is critical to fighting infections and disease. The molecular recognition of harmful entities takes place when antigen-presenting cells (APC) harboring major histocompatibility complex (MHC) molecules bound to peptides derived from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeef69858eb4e4e3b5f3e0671eba206f
https://doi.org/10.1101/2022.02.25.481189
https://doi.org/10.1101/2022.02.25.481189
Autor:
Chushu Li, Dawei Chen, Xun Guo, Hao Chi, Han Yao, Jing-Yuan Fang, Huanbin Wang, Xu Jie, Yungang Wang, Fang He, Shouyan Deng
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThe abnormal upregulation of programmed death-ligand 1 (PD-L1) in cancer cells inhibits T cell-mediated cytotoxicity, but the molecular mechanisms that drive and maintain PD-L1 expression are still incompletely understood.MethodsCombined an
Publikováno v:
Advances in experimental medicine and biology. 1248
Immune checkpoints are variegated stimulatory and inhibitory signals that are fundamental in immune homeostasis. The regulative molecules for immune checkpoints include programmed cell death protein 1 (PD1), programmed death-ligand 1 or 2 (PD-L1 or P
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9789811532658
Immune checkpoints are variegated stimulatory and inhibitory signals that are fundamental in immune homeostasis. The regulative molecules for immune checkpoints include programmed cell death protein 1 (PD1), programmed death-ligand 1 or 2 (PD-L1 or P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b10ce3cb82a9bc96841ceee7b41c7fd
https://doi.org/10.1007/978-981-15-3266-5_18
https://doi.org/10.1007/978-981-15-3266-5_18